Upper Tract Urothelial Carcinoma

Some patients with high-risk upper tract urothelial carcinoma experience pathologic downstaging following preoperative chemotherapy.

In a small pilot study, all 16 UTUC patients experienced a complete or partial response to IMRT.

A study found that patients with more advanced-stage upper tract urothelial carcinoma had a higher prevalence of lymph node metastasis.

In a study, high PTRF expression indicated clinically aggressive UTUC in both Taiwanese and Caucasian patients.

In a phase 3 trial, mitomycin gel for instillation showed a complete response rate of 59% of patients with low-grade upper tract urothelial cancer.

A meta-analysis comparing segmental ureterectomy and radical nephroureterectomy for UTUC suggests that selected patients, such as those with low-risk ureteral tumors, might benefit from segmental ureterectomy.

Chemotherapy should be considered part of multi-modal treatment for nonmetastatic UTUC patients when clinically feasible, according to researchers.

For some UTUC patients, adjuvant chemotherapy may improve survival over radical nephroureterectomy alone,

In a small study of patients without a history of bladder cancer who undergo radical nephroureterectomy for upper tract urothelial carcinoma, preoperative pyuria was associated with a 1.7-fold increased risk of intravesical recurrence, a study found.